UK shareholder meetings calendar - next 7 days
22nd Jan 2026 17:13
| Price | 11.60p on 27-01-2026 at 06:00:02 |
|---|---|
| Change | -0.20p -1.72% |
| Buy | 0.00p |
| Sell | 0.00p |
| Last Trade: | Buy 12,000.00 at 11.60p |
| Day's Volume: | 0 |
| Last Close: | 11.60p |
| Open: | 11.90p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 11.60p - 11.90p |
| 52wk Range: | 5.25p - 12.10p |
| Market Capitalisation: | £712.41m |
| VWAP: | 0.00p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 12,000 | 11.60p | Suspected BUY Trade |
16:35:00 - 26-Jan-26 |
| Sell* | 9,494 | 10.575p | Ordinary |
14:01:57 - 26-Jan-26 |
| Buy* | 10,000 | 11.90p | Suspected BUY Trade |
14:00:19 - 26-Jan-26 |
| Sell* | 6,578 | 10.575p | Ordinary |
12:55:10 - 26-Jan-26 |
| Sell* | 11,133 | 10.575p | Ordinary |
12:54:44 - 26-Jan-26 |
| Buy* | 2,500 | 11.40p | Ordinary |
11:54:55 - 26-Jan-26 |
| Buy* | 85 | 12.00p | Ordinary |
09:57:49 - 26-Jan-26 |
| Sell* | 330 | 10.515p | Ordinary |
09:57:09 - 26-Jan-26 |
| Buy* | 7,000 | 11.90p | Suspected BUY Trade |
09:00:01 - 26-Jan-26 |
| Buy* | 790 | 11.444p | Ordinary |
08:14:55 - 26-Jan-26 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 19th Jan 2026 7:00 am | RNS | Half Year Trading Update |
| 6th Jan 2026 7:00 am | RNS | Notice of 2025 Annual General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 16th Dec 2025 7:00 am | RNS | Grassmuno® marketing authorisation in Germany |
| 12th Dec 2025 7:00 am | RNS | Authority for allotment of New Shares |
| 11th Dec 2025 7:00 am | RNS | Prelim Results and publication of Annual Report |
| 9th Dec 2025 7:00 am | RNS | Primary Safety Endpoint Met in PROTECT trial |
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |